Crinetics Pharmaceuticals Inc
NASDAQ:CRNX
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
25.56
56.43
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Wall Street
Price Targets
CRNX Price Targets Summary
Crinetics Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for
CRNX
is 85.75 USD
with a low forecast of 55.55 USD and a high forecast of 110.25 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is CRNX's stock price target?
Price Target
85.75
USD
According to Wall Street analysts, the average 1-year price target for
CRNX
is 85.75 USD
with a low forecast of 55.55 USD and a high forecast of 110.25 USD.
What is Crinetics Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
380%
For the last 7 years the
compound annual growth rate for
Crinetics Pharmaceuticals Inc's revenue is
-9%.
The projected
CAGR
for the next 4 years is
380%.
